Year: 2012
Type: editorial
Abstract: regimen for this patient population.The results of Burnett et al, supported by those recently published by Castaigne et al, 5 merit reconsideration of the availability of GO as a component of therapy for older patients newly diagnosed with AML.
Source: Journal of Clinical Oncology
Author: Donna S. Neuberg
Institution: Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1971924948